Vaxcyte
Developing superior and novel vaccines designed to treat some of the most common and deadly infectious diseases
San Carlos, United States
543 employees
IPO
Total: $4.41B
Biopharma, Biotechnology +2
General Information
San Carlos, United States
BounceWatch is an independent company data service, not affiliated with Vaxcyte. To contact Vaxcyte, visit vaxcyte.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Vaxcyte compare?
A PDF of Vaxcyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Vaxcyte soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biopharma
About Vaxcyte
Funding Rounds & Investors (11)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $632.50M | - |
|
01 Feb 2026 |
| Post-IPO Equity | $1.30B | - |
|
01 Sep 2024 |
| Post-IPO Equity | $750.00M | - |
|
01 Jan 2024 |
| Post-IPO Equity | $500.00M | - |
|
01 Apr 2023 |
| Post-IPO Equity | $600.00M | - |
|
01 Oct 2022 |
| Secondary Market | $100.00M | - |
|
01 Jan 2022 |
| IPO | $250.00M | - |
|
01 Jun 2020 |
| Series D | $110.00M | 10 |
|
01 Mar 2020 |
| Series C | $85.00M | 6 |
|
01 Jun 2018 |
| Series B | $64.00M | 5 |
|
01 Mar 2017 |
Latest News
View All
FAQ About Vaxcyte
Source: BounceWatch company record for Vaxcyte, https://bouncewatch.com/company/vaxcyte, updated 9 June 2026. When citing, please name BounceWatch and link this page.
